

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HANGZHOU TIGERMED CONSULTING CO., LTD.

杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

2024 THIRD QUARTERLY REPORT

This announcement is made pursuant to Rules 13.09(2) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The following is the third quarterly report of Hangzhou Tigermed Consulting Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”). This announcement and the accompanying financial statements were originally prepared in Chinese and published in both English and Chinese. If there is any inconsistency or conflict between the Chinese and English versions, the Chinese version shall prevail.

Shareholders of the Company and public investors should note that the accompanying financial statements were prepared in accordance with the China Accounting Standards for Business Enterprises and have not been audited.

By order of the Board
Hangzhou Tigermed Consulting Co., Ltd.
Ye Xiaoping
Chairman

Hong Kong, October 29, 2024

As at the date of this announcement, the executive directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun, Mr. Wu Hao and Mr. Wen Zengyu; the independent non-executive directors are Mr. Liu Kai Yu Kenneth, Mr. Yuan Huagang and Ms. Liu Yuwen.

Hangzhou Tigermed Consulting Co., Ltd.
2024 THIRD QUARTERLY REPORT

The Company and all members of the Board of Directors warrant that the information disclosed is true, accurate and complete and there is no false representation, misleading statement or material omission.

IMPORTANT NOTICE:

1. The Board of Directors, Board of Supervisors, Directors, Supervisors and senior management warrant that the contents of the quarterly report are true, accurate and complete and there is no false representation, misleading statement or material omission, and take legal responsibilities jointly and severally.
2. The head of the Company, person-in-charge of accounting affairs and head of accounting department (accounting supervisor) warrant the truthfulness, accuracy and completeness of the financial information contained in this quarterly report.
3. Whether the third quarterly report is audited
 Yes No

I. KEY FINANCIAL DATA

(I) Major accounting data and financial indicators

Whether retrospective adjustments or restatements would be made by the Company to the accounting data for prior years

Yes No

	Reporting Period	Change	From the beginning of the year to the end of the Reporting Period	Change
Revenue (RMB)	1,709,371,136.50	-11.87%	5,067,615,359.89	-10.32%
Net profit attributable to shareholders of the listed company (RMB)	320,580,064.49	-34.74%	813,428,915.46	-56.72%
Net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss (RMB)	251,772,880.13	-37.83%	892,098,006.45	-25.56%
Net cash flows from operating activities (RMB)	—	—	578,769,609.95	-13.96%
Basic earnings per share (RMB/share)	0.37	-35.09%	0.94	-56.68%
Diluted earnings per share (RMB/share)	0.37	-35.09%	0.94	-56.68%
Weighted average return on net assets	1.53%	-0.83%	3.85%	-5.36%
	End of the Reporting Period		End of prior year	Change
Total assets (RMB)	30,276,592,021.30		29,680,742,349.17	2.01%
Owners' equity attributable to shareholders of the listed company (RMB)	21,064,966,698.75		21,026,774,725.75	0.18%

Note: The Reporting Period shall mean a period of three months from the beginning of this quarter to the end of this quarter, the same below.

(II) Items and amounts of extraordinary gain or loss Applicable Not applicable*Unit: RMB*

Item	Amount for the Reporting Period	Amount from the beginning of the year to the end of the Reporting Period	Remarks
Gain or loss from disposal of non-current assets (including those already written off in the provision for asset impairment)	1,185,208.54	2,674,931.25	Mainly due to the disposal of long-term assets such as long-term equity investments and fixed assets by the Company during the Reporting Period.
Government grants (except for government grants which are closely related to the ordinary business scope of the Company and entitled in defined standard in conformity with the provisions of policies of the State and that have a sustained impact on the Company's profit or loss) included in the profit or loss for the period	4,804,259.75	22,330,426.78	Mainly due to the government grants received by the Company during the Reporting Period.
Profit or loss arising from changes in fair value of financial assets and financial liabilities held by non-financial companies and profit or loss arising from the disposal of financial assets and financial liabilities (except for those related to effective hedging businesses under ordinary business scope of the Company)	65,431,400.55	12,890,140.60	Mainly due to the investment income recognized from the holding and disposal of other non-current financial assets and gains from changes in fair value of other non-current financial assets of the Company during the Reporting Period.
Gain or loss from investments on trust or asset management	30,936,897.89	52,583,716.73	Mainly due to the income from certificates of deposit and wealth management products of the Company during the Reporting Period.

Item	Amount for the Reporting Period	Amount from the beginning of the year to the end of the Reporting Period	Remarks
One-off share-based payment expense recognised as a result of cancellation and modification of the share incentive scheme	0.00	-34,508,177.28	
Other non-operating income and expenses apart from the above items	-1,510,184.83	-2,170,358.08	
Less: Effect of income tax	6,673,618.11	40,245,256.19	
Effect of minority interests (after tax)	25,366,779.43	92,224,514.80	
Total	68,807,184.36	-78,669,090.99	-

Details of other profit or loss items meeting the definition of extraordinary gain or loss:

Applicable Not applicable

There was no other profit or loss items that meet the definition of extraordinary gain or loss.

Explanation on extraordinary gain or loss items defined as recurring gain or loss items as illustrated in the Notice on Explanation of Information Disclosure of Companies Publicly Issuing Securities No.1 – Extraordinary Gain or Loss

Applicable Not applicable

There was no item of extraordinary gain or loss defined as item of recurring gain or loss as illustrated in the Notice on Explanation of Information Disclosure of Companies Publicly Issuing Securities No.1 – Extraordinary Gain or Loss.

(III) Changes in key accounting data and financial indicators and the reasons thereof

Applicable Not applicable

1. Explanation of anomalies for balance sheet items and the reasons thereof

Item	Closing balance (RMB)	Opening balance (RMB)	Change	Reason(s) for change
Cash at bank and on hand	1,967,632,936.81	7,419,991,842.25	-73.48%	Mainly due to the certificate of deposit acquired by the Company during the Reporting Period being listed under other non-current assets, and the share repurchases and purchase of minority interests.
Financial assets held for trading	76,300,000.00	42,138,295.67	81.07%	Mainly due to the purchase of wealth management products by the Company during the Reporting Period.
Notes receivable	3,674,560.00	214,560.00	1612.60%	Mainly due to the receipt of bank acceptance notes from customers by the Company during the Reporting Period.
Advances to suppliers	119,048,268.73	56,545,630.65	110.53%	Mainly due to the increase in service fee prepayments of the Company during the Reporting Period.
Construction in progress	516,620,831.31	324,278,367.30	59.31%	Mainly due to the increase in investment in new office buildings and laboratory renovations by the Company during the Reporting Period.
Other non-current assets	4,420,136,943.76	156,895,649.92	2717.25%	Mainly due to the certificate of deposit acquired by the Company during the Reporting Period being listed under other non-current assets.

Item	Closing balance (RMB)	Opening balance (RMB)	Change	Reason(s) for change
Short-term borrowings	3,010,434,835.00	1,969,693,500.00	52.84%	Mainly due to the increase in short-term borrowings from banks by the Company during the Reporting Period.
Employee benefits payable	165,533,781.62	357,979,354.68	-53.76%	Mainly due to the payment of the Company's employee remuneration accrued at the end of last year during the Reporting Period.
Non-current liabilities due within one year	299,686,178.53	563,595,304.44	-46.83%	Mainly due to the repayment of long-term borrowing due within one year by the Company during the Reporting Period.
Treasury share	191,146,104.89	869,336,804.33	-78.01%	Mainly due to the cancellation of treasury share by the Company during the Reporting Period.

2. Explanation of anomalies for income statement items and the reasons thereof

Item	Amount from the beginning of the year to the end of the Reporting Period (RMB)	Amount in the same period of prior year (RMB)	Change	Reason(s) for change
Finance expenses	31,371,079.58	-105,759,422.91	-129.66%	Mainly due to the certificate of deposit acquired by the Company during the Reporting Period being included in investment income and the increase in interest expenses.
Other income	21,606,421.27	10,602,089.43	103.79%	Mainly due to the increase in government grants received by the Company during the Reporting Period.
Gain from fair value change	-34,411,947.15	710,394,312.74	-104.84%	Mainly due to the decrease in gain from fair value change arising from other non-current financial assets of the Company during the Reporting Period.
Credit impairment loss	-44,439,217.18	-33,579,759.28	32.34%	Mainly due to the increase in bad debt provision for accounts receivable and other receivables made by the Company during the Reporting Period.
Gain on disposal of assets	2,674,931.25	45,215.63	5815.94%	Mainly due to the increase in disposal of long-term assets by the Company during the Reporting Period.
Income tax expenses	183,929,494.79	286,622,443.31	-35.83%	Mainly due to the year-on-year decrease in profit before tax of the Company during the Reporting Period.

3. Explanation of anomalies for cash flow statement items and the reasons thereof

Item	Amount from the beginning of the year to the end of the Reporting Period (RMB)	Amount in the same period of prior year (RMB)	Change	Reason(s) for change
Net cash flows from investing activities	-5,723,116,899.53	-1,592,504,848.56	259.38%	Mainly due to the purchase of certificate of deposit by the Company during the Reporting Period.
Net cash flows from financing activities	-272,001,685.95	474,861,241.52	-157.28%	Mainly due to the increase in share repurchases and purchase of minority interests during the Reporting Period.

II. SHAREHOLDERS' INFORMATION

(I) Total number of ordinary shareholders and the number of preferred shareholders with voting rights restored and the shareholding of top ten shareholders

Unit: share

Total number of ordinary shareholders as at the end of the Reporting Period	53,084	Total number of preferred shareholders with voting rights restored as at the end of the Reporting Period (if any)	0
---	--------	---	---

Shareholding of top 10 shareholders (Excluding Shares Lent through Refinancing)

Name of shareholder	Nature of shareholder	Shareholding percentage	Number of shares held	Number of shares held subject to selling restrictions	Situation of pledged, marked or frozen shares	Share status	Quantity
Ye Xiaoping	Domestic natural person	20.49%	177,239,541	132,929,656	Not applicable		0
HKSCC NOMINEES LIMITED ^{Note 1}	Overseas legal person	14.23%	123,118,679	0	Not applicable		0
Cao Xiaochun	Domestic natural person	5.97%	51,661,774	38,746,330	Pledged		20,600,000

Shareholding of top 10 shareholders (Excluding Shares Lent through Refinancing)

Name of shareholder	Nature of shareholder	Shareholding percentage	Number of shares held	Number of shares held subject to selling restrictions	Situation of pledged, marked or frozen shares	
					Share status	Quantity
Industrial and Commercial Bank of China Limited – China-Europe Medical and Health Hybrid Securities Investment Fund	Others	3.48%	30,077,282	0	Not applicable	0
Hong Kong Securities Clearing Company Limited	Overseas legal person	2.65%	22,936,271	0	Not applicable	0
Bank of China Limited – Huabao CSI Medical Trading Open-ended Index Securities Investment Fund	Others	2.08%	17,956,750	0	Not applicable	0
Industrial and Commercial Bank of China Limited – E Fund GEM Trading Open – end Index Securities Investment Fund	Others	1.69%	14,631,783	0	Not applicable	0
Shi Xiaoli	Domestic natural person	1.16%	10,031,703	0	Not applicable	0
Industrial and Commercial Bank of China Limited – Huatai-PB CSI 300 Open-ended Index Fund	Others	1.16%	10,004,766	0	Not applicable	0
China Everbright Bank Company Limited – AegonIndustrial Commercial Mode Preferred Hybrid Securities Investment Fund (LOF)	Others	1.15%	9,971,653	0	Not applicable	0

**Shareholding of the top 10 shareholders not subject to selling restrictions
(Excluding Shares Lent through Refinancing or restricted of Senior Management)**

Name of shareholder	Number of shares held not subject to selling restrictions	Class and number of shares	Quantity
HKSCC NOMINEES LIMITED	123,118,679	Overseas listed foreign shares	123,118,679
Ye Xiaoping	44,309,885	Renminbi ordinary shares	44,309,885
Industrial and Commercial Bank of China Limited – China – Europe Medical and Health Hybrid Securities Investment Fund	30,077,282	Renminbi ordinary shares	30,077,282
Hong Kong Securities Clearing Company Limited	22,936,271	Renminbi ordinary shares	22,936,271
Bank of China Limited – Huabao CSI Medical Trading Open – ended Index Securities Investment Fund	17,956,750	Renminbi ordinary shares	17,956,750
Industrial and Commercial Bank of China Limited – E Fund GEM Trading Open – end Index Securities Investment Fund	14,631,783	Renminbi ordinary shares	14,631,783
Cao Xiaochun	12,915,444	Renminbi ordinary shares	12,915,444
Shi Xiaoli	10,031,703	Renminbi ordinary shares	10,031,703
Industrial and Commercial Bank of China Limited – Huatai-PB CSI 300 Open-ended Index Fund	10,004,766	Renminbi ordinary shares	10,004,766
China Everbright Bank Company Limited – AegonIndustrial Commercial Mode Preferred Hybrid Securities Investment Fund (LOF)	9,971,653	Renminbi ordinary shares	9,971,653
Explanation of the shareholders above who are connected or acting in concert	Ye Xiaoping and Cao Xiaochun signed the Acting-in-Concert Agreement, pursuant to which the two are persons acting in concert and the de facto controllers of the Company.		
Description of top 10 shareholders participating in the margin trading business (if any)	Nil		

Note 1: HKSCC NOMINEES LIMITED holds shares on behalf of its multiple clients.

Shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of outstanding shares not subject to selling restrictions participating in lending shares through shares lending and refinancing business

Applicable Not applicable

Changes in the top 10 shareholders and the top 10 shareholders of outstanding shares not subject to selling restriction compared with the previous period due to lending/returning shares through shares lending and refinancing

Applicable Not applicable

(II) Total number of preferred shareholders of the Company and the shareholding of top 10 preferred shareholders

Applicable Not applicable

(III) Changes in restricted shares

Applicable Not applicable

Unit: share

Name of shareholder	Number of restricted shares at the beginning of the period	Number of restricted shares unlocked during the period	Number of restricted shares increased during the period	Number of restricted shares at the end of the period	Reasons for the restriction	Proposed date of unlocking the restricted shares
Ye Xiaoping	132,929,656	0	0	132,929,656	Lock-up for senior management	25% of the shares subject to lock-up for senior management to be unlocked annually
Cao Xiaochun	38,746,330	0	0	38,746,330	Lock-up for senior management	25% of the shares subject to lock-up for senior management to be unlocked annually
Li Xiaori	11,058	0	0	11,058	Lock-up for senior management	25% of the shares subject to lock-up for senior management to be unlocked annually
Total	171,687,044	0	0	171,687,044	-	-

III. OTHER SIGNIFICANT EVENTS

Applicable Not applicable

1. On February 27, 2024, the Company held the fifth meeting of the fifth session of Board of Directors to consider and approve the Resolution on the By-Election of the Independent Non-executive Director of the Fifth Session of Board of Directors of the Company (《關於補選公司第五屆董事會獨立非執行董事的議案》). In view of the fact that Ms. Yang Bo has applied for resignation as an independent non-executive Director of the Company due to personal work reasons, and after the qualification review by the Nomination Committee of the Company's Board of Directors, the Company's Board of Directors nominated Ms. Liu Yuwen as an independent non-executive Director candidate for the fifth session of the Board of Directors of the Company, with a term commencing from the date of the approval by Shareholders at the general meeting of the Company until the conclusion of the fifth session of the Board of Directors. On March 21, 2024, the Company held the first extraordinary general meeting for 2024 to consider and approve the Resolution on the By-election of Independent Non-executive Director of the Fifth Session of the Board of Directors of the Company. For details, please refer to the Company's relevant announcements published on cninfo.com on February 28 and March 21, 2024.
2. On September 27, 2024, the Company held the eleventh meeting of the fifth session Board of Directors to consider and approve the Resolution on Outbound Investment and Connected Transaction (《關於對外投資暨關聯交易的議案》), where the Company intends to acquire the 35.8322% equity of Teddy Clinical Research Laboratory (Shanghai) Limited (上海觀合醫藥科技股份有限公司) ("Teddy Clinical") held by Dian Diagnostics Group Co., Ltd. (迪安診斷技術集團股份有限公司) ("Dian Diagnostics"), 5.2200% property share of Zhuji Guanhe Enterprise Management Partnership (Limited Partnership) (諸暨觀鶴企業管理合夥企業(有限合夥)), 4.8883% property share of Zhuji Guanhe Phase III Enterprise Management Partnership (Limited Partnership) (諸暨觀荷三期企業管理合夥企業(有限合夥)), 2.5500% property share of Zhuji Guanhe Phase IV Enterprise Management Partnership (Limited Partnership) (諸暨觀合四期企業管理合夥企業(有限合夥)) held by Dian Diagnostics in cash and 3.6939% equity of Teddy Clinical held by Suzhou Yingkai Xinyun Enterprise Management Consulting Co., Ltd. (蘇州瀛凱欣運企業管理諮詢有限公司) ("Suzhou Yingkai"). Upon the completion of this transaction, the Company and its wholly-owned subsidiary Jiaxing Xinge Pharmaceutical Technology Co., Ltd. (嘉興欣格醫藥科技有限公司) will directly and indirectly hold a total of 72.8169% equity of Teddy Clinical, and Teddy Clinical will be consolidated into the scope of consolidated financial statements of the Company. This transaction constituted a connected transaction, as Mr. Ye Xiaoping, being the de facto controllers of the Company and Chairman, acts as a director of Dian Diagnostics and Suzhou Yingkai is a subsidiary of Dian Diagnostics. For details, please refer to the Company's relevant announcements published on cninfo.com on September 28, 2024.

IV. QUARTERLY FINANCIAL STATEMENTS

(I) FINANCIAL STATEMENTS

1. Consolidated balance sheet

Prepared by: Hangzhou Tigermed Consulting Co., Ltd.

September 30, 2024

Unit: RMB

Item	Closing balance	Opening balance
Current assets:		
Cash at bank and on hand	1,967,632,936.81	7,419,991,842.25
Settlement reserve		
Placements with banks and other financial institutions		
Financial assets held for trading	76,300,000.00	42,138,295.67
Derivative financial assets		
Notes receivable	3,674,560.00	214,560.00
Accounts receivable	1,241,244,927.10	1,260,700,340.86
Accounts receivable financing		
Advances to suppliers	119,048,268.73	56,545,630.65
Premium receivables		
Amounts due from reinsurers		
Reinsurance contract reserve receivable		
Other receivables	102,962,088.09	79,577,742.45
Including: Interests receivable	16,771,156.69	19,636,120.18
Dividends receivable		
Financial assets purchased under agreements to resell		
Inventories	22,196,124.75	23,397,667.40
Including: Data resources		
Contract assets	2,940,514,164.81	2,364,435,242.53
Assets classified as held-for-sale		
Non-current assets due within one year		
Other current assets	73,947,764.66	97,139,803.40
Total current assets	6,547,520,834.95	11,344,141,125.21

Item	Closing balance	Opening balance
Non-current assets:		
Loans and advances to customers		
Bond investments		
Other bond investments		
Long-term receivables		
Long-term equity investments	3,515,279,694.87	2,977,027,510.07
Other equity instruments investment	10,629,739.38	14,507,959.32
Other non-current financial assets	10,716,445,742.86	10,231,701,776.67
Investment properties		
Fixed assets	584,711,474.52	638,751,357.57
Construction in progress	516,620,831.31	324,278,367.30
Productive biological assets		
Oil and gas assets		
Right-of-use assets	509,187,439.20	509,578,081.32
Intangible assets	325,329,299.93	371,129,876.93
Including: Data resources		
Development disbursements		
Including: Data resources		
Goodwill	2,810,082,693.50	2,764,188,189.08
Long-term deferred expenses	189,271,411.97	213,751,116.95
Deferred tax assets	131,375,915.05	134,791,338.83
Other non-current assets	4,420,136,943.76	156,895,649.92
Total non-current assets	23,729,071,186.35	18,336,601,223.96
Total assets	30,276,592,021.30	29,680,742,349.17

Item	Closing balance	Opening balance
Current liabilities:		
Short-term borrowings	3,010,434,835.00	1,969,693,500.00
Due to central banks		
Placements from banks and other financial institutions		
Financial liabilities held for trading		
Derivative financial liabilities		
Notes payable	1,598,000.00	
Accounts payable	228,330,730.46	249,307,924.54
Advanced receipts		
Contract liabilities	809,815,727.76	680,489,184.98
Financial assets sold under agreement to repurchase		
Customer deposits and placements from other financial institutions		
Customer brokerage deposits		
Securities underwriting brokerage deposits		
Employee benefits payable	165,533,781.62	357,979,354.68
Tax payable	174,553,344.24	220,759,136.97
Other payables	83,945,580.68	78,673,426.67
Including: Interests payable	3,620,817.53	6,392,172.03
Dividends payable	1,823,888.87	3,470,035.91
Fees and commissions payable		
Amounts due to reinsurer		
Liabilities classified as held-for-sale		
Non-current liabilities due within one year	299,686,178.53	563,595,304.44
Other current liabilities	21,359,578.54	18,238,459.30
Total current liabilities	4,795,257,756.83	4,138,736,291.58

Item	Closing balance	Opening balance
Non-current liabilities:		
Reserve of insurance contract		
Long-term borrowings	397,237,083.72	434,223,304.63
Bonds payable		
Including: Preferred shares		
Perpetual bonds		
Lease liabilities	444,120,824.43	423,108,703.51
Long-term payables		
Long-term employee benefits payable	2,441,425.78	2,538,825.71
Provisions		
Deferred revenue	14,111,379.63	14,594,433.99
Deferred tax liabilities	204,624,399.71	213,978,644.49
Other non-current liabilities		
Total non-current liabilities	1,062,535,113.27	1,088,443,912.33
Total liabilities	5,857,792,870.10	5,227,180,203.91
Owners' equity:		
Share capital	864,948,570.00	872,418,220.00
Other equity instruments		
Including: Preferred shares		
Perpetual bonds		
Capital surplus	10,780,324,919.18	11,708,834,896.63
Less: Treasury stock	191,146,104.89	869,336,804.33
Other comprehensive income	77,377,043.56	103,534,270.25
Special reserve		
Surplus reserve	436,529,393.76	436,529,393.76
General risk provision		
Retained earnings	9,096,932,877.14	8,774,794,749.44
Total equity attributable to owners of the parent	21,064,966,698.75	21,026,774,725.75
Non-controlling interests	3,353,832,452.45	3,426,787,419.51
Total owners' equity	24,418,799,151.20	24,453,562,145.26
Total liabilities and owners' equity	30,276,592,021.30	29,680,742,349.17

Legal representative:

Cao Xiaochun

*Person-in-charge of
accounting:*

Yang Chengcheng

*Head of accounting
department:*

Xia Jiangmei

2. Consolidated income statement from the beginning of the year to the end of the Reporting Period

Unit: RMB

Item	Amount for the Reporting Period	Amount for the prior period
I. Total revenue	5,067,615,359.89	5,650,477,938.01
Including: Operating income	5,067,615,359.89	5,650,477,938.01
Interest income		
Premium earned		
Fees and commission income		
II. Total cost of sales	4,026,550,519.06	4,142,186,555.14
Including: Operating cost	3,097,333,423.23	3,370,920,132.80
Interest expenses		
Fees and commission expenses		
Cash surrender value		
Claim settlement expenses, net		
Net provision of insurance contract liabilities		
Policy dividend expense		
Reinsurance expenses		
Business tax and surcharge	22,385,614.14	21,435,986.03
Selling expenses	144,935,323.39	132,703,603.93
General and administrative expenses	558,426,318.44	527,543,104.76
Research and development expenses	172,098,760.28	195,343,150.53
Finance expenses	31,371,079.58	-105,759,422.91
Including: Interest expenses		
Interest income		
Add: Other income	21,606,421.27	10,602,089.43
Investment income (losses are expressed by “-”)	109,158,171.38	127,735,432.89
Including: Income from investment in associates and joint ventures		
Gain on de-recognition of financial assets at amortized cost		
Foreign exchange gain (losses are expressed by “-”)		
Net exposure hedging gain (losses are expressed by “-”)		
Gain from fair value change (losses are expressed by “-”)	-34,411,947.15	710,394,312.74
Credit impairment loss (losses are expressed by “-”)	-44,439,217.18	-33,579,759.28
Asset impairment loss (losses are expressed by “-”)	-10,657,299.51	-11,764,401.66
Gain on disposal of assets (losses are expressed by “-”)	2,674,931.25	45,215.63

Item	Amount for the Reporting Period	Amount for the prior period
III. Operating profit (losses are expressed by “-”)	1,084,995,900.89	2,311,724,272.62
Add: Non-operating income	5,337,204.28	6,871,087.04
Less: Non-operating expenses	3,268,133.42	4,125,944.61
IV. Total profits (total losses are expressed by “-”)	1,087,064,971.75	2,314,469,415.05
Less: Income tax expenses	183,929,494.79	286,622,443.31
V. Net profits (net losses are expressed by “-”)	903,135,476.96	2,027,846,971.74
(I) Classified by continuing operations		
1. Net profits from continuing operations (net losses are expressed by “-”)	903,135,476.96	2,027,846,971.74
2. Net profits from discontinued operations (net losses are expressed by “-”)		
(II) Classified by ownership of equity		
1. Net profits attributable to shareholders of the parent	813,428,915.46	1,879,604,430.16
2. Non-controlling interests (net losses are expressed by “-”)	89,706,561.50	148,242,541.58
VI. Other comprehensive income, net of tax	-50,709,884.36	66,970,735.88
Other comprehensive income attributable to owners of the parent, net of tax	-26,157,226.69	41,438,207.71
(I) Items that will not be reclassified subsequently to profit or loss	-1,725,389.26	
1. Changes arising from re-measurement of defined benefit obligation		
2. Other comprehensive income accounted for using the equity method, which will not be reclassified subsequently to profit or loss	-1,725,389.26	
3. Change in fair value of other equity instruments investment		
4. Change in fair value of credit risk of the Company		
5. Others		

Item	Amount for the Reporting Period	Amount for the prior period
(II) Items that may be reclassified to profit or loss	-24,431,837.43	41,438,207.71
1. Other comprehensive income accounted for using the equity method, which may be reclassified subsequently to profit or loss		
2. Change in fair value of other bond investments		
3. Other comprehensive income due to reclassification of financial assets		
4. Credit impairment loss on other bond investments		
5. Cash flow hedge reserve		
6. Currency translation difference	-24,431,837.43	41,438,207.71
7. Others		
Other comprehensive income attributable to non-controlling interests, net of tax	-24,552,657.67	25,532,528.17
VII. Total comprehensive income	852,425,592.60	2,094,817,707.62
(I) Total comprehensive income attributable to owners of the parent	787,271,688.77	1,921,042,637.87
(II) Total comprehensive income attributable to non-controlling interests	65,153,903.83	173,775,069.75
VIII. Earnings per share:		
(I) Basic earnings per share	0.94	2.17
(II) Diluted earnings per share	0.94	2.17

For the business combination under common control in the current period, the net profit realized by the acquiree before the combination was RMB0.00, and the net profit realized by the acquiree in the prior period was RMB0.00.

<i>Legal representative:</i>	<i>Person-in-charge of accounting:</i>	<i>Head of accounting department:</i>
Cao Xiaochun	Yang Chengcheng	Xia Jiangmei

3. Consolidated cash flow statement from the beginning of the year to the end of the Reporting Period

Unit: RMB

Item	Amount for the Reporting Period	Amount for the prior period
I. Cash flows from operating activities:		
Cash received from sale of goods or rendering of services	4,856,126,172.22	5,043,275,819.72
Net increase in customer deposits and placements from other banks		
Net increase in due to central bank		
Net increase in borrowings from other financial institutions		
Cash from premiums on original insurance contracts		
Cash received from reinsurance business, net		
Net increase in insured's deposits and investments		
Cash received from interest, fees and commissions		
Net increase in placements from banks and other financial institutions		
Net increase of funds in repurchase business		
Net cash received from customer brokerage		
Tax refunds	2,149,719.16	13,496,958.97
Cash receipts related to other operating activities	135,443,635.26	246,618,696.13
Sub-total of cash inflows from operating activities	4,993,719,526.64	5,303,391,474.82
Cash paid for goods and services	1,378,495,566.27	1,585,303,250.10
Net increase in loans and advances to customers		
Net increase in deposits with central bank and other banks		
Cash paid for claim settlements on original insurance contracts		
Net increase in placements with banks and other financial institutions		
Cash paid for interest, fees and commissions		
Cash paid for policy dividends		
Cash paid to and for employee benefits	2,298,577,074.56	2,239,495,755.41
Payments of all types of taxes	436,973,562.51	481,854,173.19
Cash payments related to other operating activities	300,903,713.35	324,093,814.56
Sub-total of cash outflows from operating activities	4,414,949,916.69	4,630,746,993.26
Net cash flows from operating activities	578,769,609.95	672,644,481.56

Item	Amount for the Reporting Period	Amount for the prior period
II. Cash flows from investing activities:		
Cash received from sale of investments	619,025,446.77	655,787,863.24
Cash receipts from returns on investments	33,510,950.69	20,904,699.50
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	188,383.44	4,796,524.80
Net cash received from disposal of subsidiaries and other business units		
Cash receipts related to other investing activities	14,687,103.15	49,218,222.03
Sub-total of cash inflows from investing activities	667,411,884.05	730,707,309.57
Cash paid to acquire fixed assets, intangible assets and other long-term assets	278,061,741.81	212,954,200.90
Cash paid for investments	6,091,185,860.30	1,735,920,304.15
Net increase in pledged loans		
Net cash paid for acquisition of subsidiaries and other business units	20,964,321.47	344,200,483.90
Cash payments related to other investing activities	316,860.00	30,137,169.18
Sub-total of cash outflows from investing activities	6,390,528,783.58	2,323,212,158.13
Net cash flows from investing activities	-5,723,116,899.53	-1,592,504,848.56
III. Cash flows from financing activities:		
Cash receipts from capital contributions	61,900,000.00	246,021,485.15
Including: Cash receipts from capital contributions from non-controlling interests of subsidiaries		
Cash received from borrowings	2,843,516,597.92	2,807,145,394.97
Cash receipts related to other financing activities	107,255,379.29	4,518,909.42
Sub-total of cash inflows from financing activities	3,012,671,977.21	3,057,685,789.54
Cash repayments for debts	2,035,406,823.68	1,845,119,104.61
Cash payments for distribution of dividends, profits or interest expenses	608,854,337.03	570,880,007.09
Including: Dividends and profits paid to non- controlling interests by subsidiaries		
Cash payments related to other financing activities	640,412,502.45	166,825,436.32
Sub-total of cash outflows from financing activities	3,284,673,663.16	2,582,824,548.02
Net cash flows from financing activities	-272,001,685.95	474,861,241.52
IV. Effect of change in foreign exchange rates on cash and cash equivalents	-21,705,538.24	22,207,055.14
V. Net increase in cash and cash equivalents	-5,438,054,513.77	-422,792,070.34
Add: Cash and cash equivalents at the beginning of the period	7,399,941,369.85	7,782,740,887.02
VI. Cash and cash equivalents at the end of the period	1,961,886,856.08	7,359,948,816.68

(II) Particulars in relation to adjustments made to the financial statements as at the beginning of the year of the initial adoption of new accounting standards since 2024

Applicable Not applicable

(III) AUDIT REPORT

Whether the third quarterly report is audited

Yes No

The third quarterly report of the Company is unaudited.

The Board of Directors of Hangzhou Tigermed Consulting Co., Ltd.

October 29, 2024